Phage-tail-like bacteriocins as a biomedical platform to counter anti-microbial resistant pathogens

Bhattacharjee, Rahul; Nandi, Aditya; Sinha, Adrija; Kumar, Hemant; Mitra, Disha; Mojumdar, Abhik; Patel, Paritosh; Jha, Ealisha; Mishra, Sarita; Rout, Prabhat Kumar; Panda, Pritam Kumar; Suar, Mrutyunjay; Verma, Suresh K.

doi:10.1016/j.biopha.2022.113720

Cited by 8 publications

(3 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 1990 up to the present, the interest in these particles has continued, with the visualization of the dynamics of their production, explosive release and killing activity and studies of their regulation ( Matsui et al, 1993 ; Sun et al, 2014 ; Penterman et al, 2014b ; Fernandez et al, 2020 ; Vacheron et al, 2021 ; Bronson et al, 2022 ), their atomic structures and molecular mechanics ( Heymann et al, 2013 ; Ge et al, 2015 , 2020 ; Desfosses et al, 2019 ; Jiang et al, 2019 ; Fraser et al, 2021 ), their role in bacterial competition ( Heo et al, 2007 ; Waite and Curtis, 2009 ; Dorosky et al, 2017 , 2018 ; Oluyombo et al, 2019 ; Vacheron et al, 2021 ; Heiman et al, 2022 ) and their potential medical use ( Scholl and Martin, 2008 ; Scholl et al, 2009 ; Ritchie et al, 2011 ; Redero et al, 2020 ; Alqahtani et al, 2021 ; Six et al, 2021 ; Bhattacharjee et al, 2022 ) as well as their application as prophylactic or curative treatment against phytopathogens in agriculture ( Fernandez et al, 2017 ; Príncipe et al, 2018 ; Baltrus et al, 2022 ). Recent studies have also re-engineered eCIS structures to target new cell types and to deliver new proteins, opening new avenues for the usage of these particles ( Scholl, 2017 ; Bhattacharjee et al, 2022 ; Jiang et al, 2022 ; Kreitz et al, 2023 ).…”

Section: A Brief History Of Ecissmentioning

confidence: 99%

“…Recent studies have placed their efforts in re-engineering eCISs to modify and/or broaden their spectrum of activity, which brings hope for new treatment of multi-drug resistant pathogenic bacteria ( Williams et al, 2008 ; Scholl, 2017 ; Alqahtani et al, 2022 ; Bhattacharjee et al, 2022 ). Indeed, recombinant R-tailocins with modified tail fibers and new target specificities have been used to treat P. aeruginosa infected wounds in mice ( Alqahtani et al, 2021 ), to reduce diarrhea and intestinal inflammation caused by enterohemorrhagic Escherichia coli in a rabbit model of infection ( Ritchie et al, 2011 ), and to prevent intestinal colonization of mice by the pathogen Clostridium difficile ( Gebhart et al, 2015 ).…”

Section: Biotechnological Applications Of Ecissmentioning

confidence: 99%

See 1 more Smart Citation

Evolutionary and ecological role of extracellular contractile injection systems: from threat to weapon

Heiman,

Vacheron,

Keel

2023

Front. Microbiol.

View full text Add to dashboard Cite

Contractile injection systems (CISs) are phage tail-related structures that are encoded in many bacterial genomes. These devices encompass the cell-based type VI secretion systems (T6SSs) as well as extracellular CISs (eCISs). The eCISs comprise the R-tailocins produced by various bacterial species as well as related phage tail-like structures such as the antifeeding prophages (Afps) of Serratia entomophila, the Photorhabdus virulence cassettes (PVCs), and the metamorphosis-associated contractile structures (MACs) of Pseudoalteromonas luteoviolacea. These contractile structures are released into the extracellular environment upon suicidal lysis of the producer cell and play important roles in bacterial ecology and evolution. In this review, we specifically portray the eCISs with a focus on the R-tailocins, sketch the history of their discovery and provide insights into their evolution within the bacterial host, their structures and how they are assembled and released. We then highlight ecological and evolutionary roles of eCISs and conceptualize how they can influence and shape bacterial communities. Finally, we point to their potential for biotechnological applications in medicine and agriculture.

show abstract

Section: A Brief History Of Ecissmentioning

confidence: 99%

Section: Biotechnological Applications Of Ecissmentioning

confidence: 99%

Evolutionary and ecological role of extracellular contractile injection systems: from threat to weapon

Heiman,

Vacheron,

Keel

2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Bacteriophage therapy has proven to be an effective treatment for various bacterial infections such as those affecting the skin, gastrointestinal tract, and urinary tract. Despite the potential benefits of bacteriophage therapy, there are certain obstacles that need to be addressed in order for it to be widely acknowledged and integrated as a solution for bacterial infections ( Bhattacharjee et al, 2022 ). There are several obstacles to overcome such as meeting regulatory requirements, ensuring consistent production and quality, and conducting additional clinical tests to confirm safety and effectiveness.…”

Section: Introductionmentioning

confidence: 99%

Crisis averted: a world united against the menace of multiple drug-resistant superbugs -pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal

Saeed,

Insaf,

Piracha

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

The efficacy of antibiotics and other antimicrobial agents in combating bacterial infections faces a grave peril in the form of antimicrobial resistance (AMR), an exceedingly pressing global health issue. The emergence and dissemination of drug-resistant bacteria can be attributed to the rampant overuse and misuse of antibiotics, leading to dire consequences such as organ failure and sepsis. Beyond the realm of individual health, the pervasive specter of AMR casts its ominous shadow upon the economy and society at large, resulting in protracted hospital stays, elevated medical expenditures, and diminished productivity, with particularly dire consequences for vulnerable populations. It is abundantly clear that addressing this ominous threat necessitates a concerted international endeavor encompassing the optimization of antibiotic deployment, the pursuit of novel antimicrobial compounds and therapeutic strategies, the enhancement of surveillance and monitoring of resistant bacterial strains, and the assurance of universal access to efficacious treatments. In the ongoing struggle against this encroaching menace, phage-based therapies, strategically tailored to combat AMR, offer a formidable line of defense. Furthermore, an alluring pathway forward for the development of vaccines lies in the utilization of virus-like particles (VLPs), which have demonstrated their remarkable capacity to elicit a robust immune response against bacterial infections. VLP-based vaccinations, characterized by their absence of genetic material and non-infectious nature, present a markedly safer and more stable alternative to conventional immunization protocols. Encouragingly, preclinical investigations have yielded promising results in the development of VLP vaccines targeting pivotal bacteria implicated in the AMR crisis, including Salmonella, Escherichia coli, and Clostridium difficile. Notwithstanding the undeniable potential of VLP vaccines, formidable challenges persist, including the identification of suitable bacterial markers for vaccination and the formidable prospect of bacterial pathogens evolving mechanisms to thwart the immune response. Nonetheless, the prospect of VLP-based vaccines holds great promise in the relentless fight against AMR, underscoring the need for sustained research and development endeavors. In the quest to marshal more potent defenses against AMR and to pave the way for visionary innovations, cutting-edge techniques that incorporate RNA interference, nanomedicine, and the integration of artificial intelligence are currently under rigorous scrutiny.

show abstract

Bacteriocins and Antimicrobial Peptides

Singh,

Mal,

Kalra

et al. 2024

Probiotics as Live Biotherapeutics for Veterinary and Human Health, Volume 2

View full text Add to dashboard Cite

Phage-tail-like bacteriocins as a biomedical platform to counter anti-microbial resistant pathogens

Cited by 8 publications

References 88 publications

Evolutionary and ecological role of extracellular contractile injection systems: from threat to weapon

Evolutionary and ecological role of extracellular contractile injection systems: from threat to weapon

Crisis averted: a world united against the menace of multiple drug-resistant superbugs -pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal

Bacteriocins and Antimicrobial Peptides

Contact Info

Product

Resources

About